4th Molecular Glue Drug Development Summit | Boston, MA | January 27-29, 2026

Enabling Rapid Target Selection, Discovery and Rational Design of Degrading and Non-Degrading Molecular Glue to Develop Potent, Selective and Safer Cures for Cancer and Beyond.

Molecular glues are leading the charge in the race to drug the previously undruggable, and 2025 has seen continued investment and partnerships driving innovation in this field. Returning as the industry’s only dedicated meeting, the 4th Molecular Glue Drug Development Summit brings top experts from biopharma and academia together for intimate networking and scientific content sharing. Designed to address the unique challenges of molecular glues, this meeting will provide actionable strategies to accelerate the development of safer, more selective candidates toward the clinic.

If you’re looking to lead the way in the molecular glue space, connect with the brightest minds, and gain practical insights to drive programs forward - this is your chance to solve the field’s unique challenges and shape the next wave of innovative therapies.


URLs:
Brochure: https://go.evvnt.com/3304519-0?pid=2874
Website: https://go.evvnt.com/3304519-2?pid=2874

Category: Conferences | Science, Health & Medicine | Pharmaceuticals

Prices:
Drug Developer Pricing - Conference + 2 Workshops: USD 4197.00,
Drug Developer Pricing - Conference + 1 Workshop: USD 3598.00,
Drug Developer Pricing - Conference Only: USD 2999.00,
Academic Pricing - Conference + 2 Workshops: USD 3597.00,
Academic Pricing - Conference + 1 Workshop: USD 3098.00,
Academic Pricing - Conference Only: USD 2599.00,
Service and Solution Provider Pricing - Conference + 2 Workshops: USD 5097.00,
Service and Solution Provider Pricing - Conference + 1 Workshop: USD 4398.00,
Service and Solution Provider Pricing - Conference Only: USD 3699.00

Speakers: Milad Rouhimoghadam, Senior Scientist, Abbvie, Dong Seok Kim, CEO, AevisBio Inc. , Laura Silivian, Senior Director, Biogen, Vivek Vishnudas, Chief Technology Officer, Head of Research and Development Site, BGPBio Inc., Orli Even-Or, Director of R AND D, Coltac Therapeutics, Chunhai Charlie Hao, Co-Founder, Degrome Therapeutics, Kyle Eastman, Vice President, Head of Chemistry, Halda Therapeutics LLC, Anita Bellail, Chief Executive Director, HB Therapeutics Inc. , Wu Du, Senior Vice President - Medicinal Chemistry, Hinova, Ingrid Wertz, Chief Executive Officer, Lyterian Therapeutics, Mikolaj Slabicki, Principal Investigator, Massachusetts General Hospital , Jonathan Soloman, Director, Novartis AG, John McGee, Senior Vice President of Platform Technology, Parabilis Medicines, Peggy Thompson, Vice President and Head of Biology, Plexium Inc., Rick Ewing, VP, Head of Chemistry, Rapafusyn Pharmaceuticals , Goutham Narla, Chief Scientific Officer, RAPPTA Therapeutics , Gisele Nishiguichi, Targeted Protein Degradation Center Leader, St. Jude Children's Research Hospital, Stephen Hinshaw, Senior Scientist, Stanford University , Eugene Chekler, Senior Director, Takeda Pharmaceutical, Chris Tame, Chief Executive Officer, Ternary Therapeutics, Patrick Arsenault, Senior Director, Lead Discovery, Triana Biomedicines , Dalia Barsyte Lovejoy, Principal Investigator, University of Toronto